Egetis shares jump on US drug approval

Egetis Therapeutics AB (publ)

29/09/2026 10:30

   ** Shares in rare disease drugmaker Egetis EGTX.ST surge about 13% following US FDA approval of its Emcitate drug
** Van Lanschot Kempen says the US approval unlocks the "largest opportunity" for the firm
** The broker notes Emcitate is the first effective option for MCT8 deficiency, an ultra-rare genetic condition, with the label covering thyrotoxicosis alleviation
** Van Lanschot Kempen expects "strong uptake in the identified patients" since datasets indicate survival and quality of life benefits from the newly approved medication
** The brokerage adds that a higher estimated wholesale acquisition cost, or WAC, and a priority review voucher worth up to $220 million boost the commercial outlook
     

(Reporting by Marta Frackowiak)
((marta.frackowiak@thomsonreuters.com))